For example, studies conducted in the Chinese population have evidenced that ER+ and PR+ statuses were higher among patients with serous and endometrioid carcinomas compared to mucinous and clear-cell carcinomas of malignant epithelial OC, and that ER+ and PR+ OC patients have a better clinical outcome [176]. This evidence concerns the gene PGR and clear cell adenocarcinoma.